

A worldwide crisis with nitrosamine contamination in medical products began in 2018 [1]. In drugs such as angiotensin II receptor blockers (ARBs), ranitidine, metformin, rifampin, rifapentine, and, recently, vericicline, N-nitrosodimethylamine (NDMA) and other nitrosamines have been detected [2,3]. Since then, widespread investigations by regulatory agencies, including the European Medicines Agency (EMA) and United States Food and Drug Administration (US FDA), were undertaken